Panbela Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.26 Insider Own2.10% Shs Outstand31.71M Perf Week-6.02%
Market Cap3.85M Forward P/E- EPS next Y-0.41 Insider Trans0.00% Shs Float28.10M Perf Month-11.66%
Income-33.70M PEG- EPS next Q-0.09 Inst Own9.40% Short Float / Ratio0.19% / 0.06 Perf Quarter-81.62%
Sales- P/S- EPS this Y-40.40% Inst Trans- Short Interest0.05M Perf Half Y-91.99%
Book/sh-0.40 P/B- EPS next Y73.00% ROA-381.40% Target Price9.50 Perf Year-93.65%
Cash/sh0.03 P/C4.28 EPS next 5Y- ROE- 52W Range0.10 - 2.40 Perf YTD-92.77%
Dividend- P/FCF- EPS past 5Y12.10% ROI- 52W High-94.79% Beta0.94
Dividend %- Quick Ratio0.20 Sales past 5Y- Gross Margin- 52W Low24.63% ATR0.02
Employees4 Current Ratio0.20 Sales Q/Q- Oper. Margin- RSI (14)39.34 Volatility20.50% 19.88%
OptionableNo Debt/Eq- EPS Q/Q-31.40% Profit Margin- Rel Volume1.14 Prev Close0.13
ShortableYes LT Debt/Eq- EarningsNov 10 AMC Payout- Avg Volume912.71K Price0.12
Recom2.50 SMA20-1.61% SMA50-39.29% SMA200-88.99% Volume1,028,670 Change-5.66%
Nov-28-22 09:00AM
Nov-10-22 04:10PM
Oct-31-22 09:00AM
Oct-06-22 08:00AM
Sep-30-22 08:37AM
09:00AM Loading…
Sep-29-22 09:00AM
Aug-15-22 04:10PM
Aug-11-22 09:00AM
Aug-04-22 09:00AM
Aug-01-22 04:00PM
Jun-28-22 08:00AM
Jun-16-22 08:00AM
May-12-22 04:05PM
Apr-27-22 08:30AM
Apr-26-22 08:30AM
08:30AM Loading…
Apr-12-22 08:30AM
Mar-24-22 04:05PM
Mar-23-22 08:30AM
Mar-10-22 08:30AM
Mar-08-22 08:30AM
Mar-07-22 08:30AM
Feb-22-22 08:00AM
Jan-26-22 09:00AM
Jan-24-22 09:00AM
Dec-14-21 09:00AM
Nov-18-21 09:00AM
Nov-10-21 04:15PM
Oct-25-21 09:00AM
Sep-27-21 01:08PM
Sep-07-21 09:00AM
04:12PM Loading…
Aug-11-21 04:12PM
Aug-09-21 08:00AM
Jul-28-21 09:00AM
Jul-08-21 11:20AM
Jul-07-21 08:45AM
Jul-02-21 04:05PM
Jun-30-21 12:06AM
Jun-29-21 05:25PM
Jun-23-21 09:35AM
Jun-08-21 05:07PM
Jun-04-21 09:15AM
May-26-21 08:00AM
May-12-21 04:10PM
Apr-28-21 08:00AM
Apr-15-21 08:00AM
Apr-06-21 08:15AM
Mar-29-21 07:37AM
Mar-26-21 08:40AM
Mar-25-21 04:30PM
Mar-17-21 06:02PM
Mar-15-21 08:00AM
Mar-08-21 08:00AM
Feb-18-21 11:07PM
Feb-11-21 12:50PM
Feb-10-21 08:30AM
Dec-08-20 08:00AM
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.